RE:Realityhydrabio wrote:
There are more pressures to decrease the price of generics. With the 3rd party manufacturing contracts Vanc has, their floor pricing does not put them in a position to be competitive with what the market demands for payment. Again, product listing formularies are spoken for (unless there is a competitive backorder, a new combination generic or a small niche product (like AA pharma) So the poor reps are out there slugging it out with minimal product management and PA $ to use. a few PP have backed away after taking a close look, because it is ugly. Its ugly even for the big boys in the generic space. There are companies that have gross sales of $150M that bring in only a profit of less then $1M and in some cases breakeven. This is with owning the vertical chain and manufacturing. When you see movement on the stock, its not based on net sales or growth, only on PP and pump and dump. To get products listed at wholesalers and cheer about does not help at all (unless there are listings with the wholesaler banners) I do hope for everyone's sake that something happens that will turn this boat around and not let it sink.